S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New Cash Law Will Be Disaster for Savers (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New Cash Law Will Be Disaster for Savers (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NYSE:HIMS

Hims & Hers Health (HIMS) Stock Forecast, Price & News

$6.02
-0.09 (-1.47%)
(As of 09/22/2023 ET)
Compare
Today's Range
$6.01
$6.16
50-Day Range
$6.02
$9.13
52-Week Range
$4.01
$12.34
Volume
1.29 million shs
Average Volume
1.98 million shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.75

Hims & Hers Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
95.2% Upside
$11.75 Price Target
Short Interest
Healthy
12.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.13mentions of Hims & Hers Health in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$2.25 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.15) to ($0.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

353rd out of 968 stocks

Offices & Clinics Of Medical Doctors Industry

1st out of 7 stocks


HIMS stock logo

About Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

HIMS Price History

HIMS Stock News Headlines

2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
Beauty stocks have not been pretty this year. Cosmetics retailer Ulta Beauty Inc. (NASDAQ: ULTA) and Estee Lauder Co. (NYSE: EL) shares
Hims and Hers Stock Analysis: Buy or Sell?
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Hims & Hers: Myopic Shorts, Absurdly Cheap
The Market Is Wrong On Hims & Hers Health
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Hims & Hers Q2 Earnings: Portfolio Cure
Hims (ED) Review 2023
Q2 2023 Hims & Hers Health Inc Earnings Call
See More Headlines
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

HIMS Company Calendar

Last Earnings
8/07/2023
Today
9/23/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
651
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.75
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+95.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-65,680,000.00
Pretax Margin
-6.58%

Debt

Sales & Book Value

Annual Sales
$526.92 million
Book Value
$1.50 per share

Miscellaneous

Free Float
144,276,000
Market Cap
$1.27 billion
Optionable
Optionable
Beta
0.53
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Andrew DudumMr. Andrew Dudum (Age 34)
    Co-Founder, Chairman & CEO
    Comp: $1.7M
  • Mr. Yemi Okupe (Age 37)
    Chief Financial Officer
    Comp: $804.05k
  • Ms. Melissa BairdMs. Melissa Baird (Age 45)
    Chief Operating Officer
    Comp: $917.67k
  • Ms. Irene A. Becklund (Age 38)
    Sr. VP, Controller & Principal Accounting Officer
    Comp: $361.12k
  • Ms. Soleil Teubner Boughton (Age 44)
    Chief Legal Officer & Corp. Sec.
    Comp: $782.66k
  • Mr. Mike Chi (Age 43)
    Chief Marketing Officer
    Comp: $514.77k
  • Dr. Patrick Carroll M.D. (Age 65)
    Chief Medical Officer, Member of Medical Advisory Board & Director
    Comp: $27.03k
  • Mr. Brian O'Shaughnessy
    Chief Communications Officer
  • Ms. Amee Parekh
    Sr. VP of HR
  • Mr. Jonathan Spitzer C.F.A.
    Sr. VP of Investor Relations













HIMS Stock - Frequently Asked Questions

Should I buy or sell Hims & Hers Health stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HIMS shares.
View HIMS analyst ratings
or view top-rated stocks.

What is Hims & Hers Health's stock price forecast for 2023?

10 brokers have issued 1 year price targets for Hims & Hers Health's stock. Their HIMS share price forecasts range from $5.00 to $18.00. On average, they predict the company's stock price to reach $11.75 in the next year. This suggests a possible upside of 95.2% from the stock's current price.
View analysts price targets for HIMS
or view top-rated stocks among Wall Street analysts.

How have HIMS shares performed in 2023?

Hims & Hers Health's stock was trading at $6.41 at the start of the year. Since then, HIMS stock has decreased by 6.1% and is now trading at $6.02.
View the best growth stocks for 2023 here
.

Are investors shorting Hims & Hers Health?

Hims & Hers Health saw a decline in short interest in August. As of August 31st, there was short interest totaling 16,650,000 shares, a decline of 5.8% from the August 15th total of 17,680,000 shares. Based on an average daily trading volume, of 2,990,000 shares, the days-to-cover ratio is presently 5.6 days. Currently, 12.4% of the company's shares are sold short.
View Hims & Hers Health's Short Interest
.

When is Hims & Hers Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our HIMS earnings forecast
.

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) issued its earnings results on Monday, August, 7th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.03. The company had revenue of $207.91 million for the quarter, compared to analyst estimates of $204.95 million. Hims & Hers Health had a negative net margin of 6.61% and a negative trailing twelve-month return on equity of 14.97%. Hims & Hers Health's quarterly revenue was up 83.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) earnings per share.

What guidance has Hims & Hers Health issued on next quarter's earnings?

Hims & Hers Health issued an update on its third quarter 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $217.00 million-$222.00 million, compared to the consensus revenue estimate of $213.78 million.

What is Hims & Hers Health's stock symbol?

Hims & Hers Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HIMS."

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.74%), Marshall Wace LLP (2.78%), State Street Corp (1.42%), Nuveen Asset Management LLC (1.37%), Nuveen Asset Management LLC (1.37%) and Geode Capital Management LLC (1.13%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends
.

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hims & Hers Health's stock price today?

One share of HIMS stock can currently be purchased for approximately $6.02.

How much money does Hims & Hers Health make?

Hims & Hers Health (NYSE:HIMS) has a market capitalization of $1.27 billion and generates $526.92 million in revenue each year. The company earns $-65,680,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Hims & Hers Health have?

The company employs 651 workers across the globe.

How can I contact Hims & Hers Health?

Hims & Hers Health's mailing address is 2269 CHESTNUT STREET SUITE 523, SAN FRANCISCO CA, 94123. The official website for the company is www.forhims.com. The company can be reached via phone at 415-851-0195 or via email at hims-ir@westwicke.com.

This page (NYSE:HIMS) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -